2seventy Bio, Inc. operates as cell and gene therapy company. It concentrates on the research, development, and commercialization of transformative treatments for cancer. The company was founded on April 26, 2021 and is headquartered in Cambridge, MA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Eatwell Victoria | Chief Financial Officer | Jun 03 '24 | Sale | 4.18 | 1,167 | 4,881 | 95,480 | Jun 05 07:16 PM | Snow Jessica | See Remarks | Jun 03 '24 | Sale | 4.18 | 649 | 2,714 | 55,622 | Jun 05 07:16 PM | Snow Jessica | See Remarks | May 03 '24 | Sale | 4.91 | 15 | 74 | 56,271 | May 16 06:40 PM | Casdin Capital, LLC | Director | Mar 26 '24 | Buy | 5.10 | 40,000 | 203,992 | 2,000,000 | Mar 28 08:29 PM | Casdin Capital, LLC | Director | Mar 25 '24 | Buy | 5.07 | 330,000 | 1,673,991 | 1,960,000 | Mar 25 09:44 PM | Casdin Capital, LLC | Director | Mar 22 '24 | Buy | 5.12 | 147,377 | 754,069 | 1,630,000 | Mar 25 09:44 PM | Casdin Capital, LLC | Director | Mar 21 '24 | Buy | 4.90 | 300,000 | 1,470,990 | 1,482,623 | Mar 25 09:44 PM | Leschly Nick | President and CEO | Jan 05 '24 | Sale | 3.75 | 1,554 | 5,833 | 1,085,476 | Jan 09 04:08 PM | Baird William D III | Chief Operating Officer | Jan 05 '24 | Sale | 3.75 | 1,380 | 5,180 | 161,335 | Jan 09 04:09 PM | Gregory Philip D | Chief Scientific Officer | Jan 05 '24 | Sale | 3.75 | 795 | 2,984 | 230,842 | Jan 09 04:09 PM | Leschly Nick | President and CEO | Jan 03 '24 | Sale | 3.87 | 72,312 | 279,739 | 1,087,030 | Jan 05 04:30 PM | Baird William D III | Chief Operating Officer | Jan 03 '24 | Sale | 3.87 | 33,651 | 130,179 | 162,715 | Jan 05 04:29 PM | Gregory Philip D | Chief Scientific Officer | Jan 03 '24 | Sale | 3.87 | 25,613 | 99,084 | 231,637 | Jan 05 04:30 PM | Leschly Nick | President and CEO | Aug 22 '23 | Sale | 5.49 | 9,312 | 51,090 | 1,159,342 | Aug 24 05:04 PM | Baird William D III | Chief Financial Officer | Aug 22 '23 | Sale | 5.49 | 7,031 | 38,576 | 196,366 | Aug 24 05:04 PM | Gregory Philip D | Chief Scientific Officer | Aug 22 '23 | Sale | 5.49 | 6,159 | 33,791 | 257,250 | Aug 24 05:04 PM | Kynam Capital Management, LP | 10% Owner | Aug 10 '23 | Buy | 5.92 | 515,414 | 3,049,287 | 5,953,825 | Aug 14 08:51 PM | Kynam Global Healthcare Master | 10% Owner | Aug 10 '23 | Buy | 5.92 | 515,414 | 3,049,287 | 5,953,825 | Aug 16 07:11 PM | Kynam Global Healthcare Master | 10% Owner | Aug 10 '23 | Buy | 5.96 | 86,414 | 515,027 | 5,142,111 | Aug 16 07:11 PM | Kynam Capital Management, LP | 10% Owner | Aug 10 '23 | Buy | 5.96 | 86,414 | 515,027 | 5,142,111 | Aug 14 08:51 PM | Leschly Nick | President and CEO | Aug 03 '23 | Sale | 6.13 | 9,060 | 55,499 | 1,168,654 | Aug 07 04:07 PM | Baird William D III | Chief Financial Officer | Aug 03 '23 | Sale | 6.13 | 6,906 | 42,304 | 203,397 | Aug 07 04:06 PM | Gregory Philip D | Chief Scientific Officer | Aug 03 '23 | Sale | 6.13 | 3,966 | 24,295 | 263,409 | Aug 07 04:06 PM |
|